Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Low expression of pro-apoptotic proteins Bax, Bak and Smac indicates prolonged progression-free survival in chemotherapy-treated metastatic melanoma.

GuttĂ  C, Rahman A, Aura C, Dynoodt P, Charles EM, Hirschenhahn E, Joseph J, Wouters J, de Chaumont C, Rafferty M, Warren M, van den Oord JJ, Gallagher WM, Rehm M.

Cell Death Dis. 2020 Feb 13;11(2):124. doi: 10.1038/s41419-020-2309-3.

2.

Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.

Buus R, Sestak I, Barron S, Loughman T, Fender B, Ruiz CL, Dynoodt P, Wang CA, O'Leary D, Gallagher WM, Dowsett M, Cuzick J.

Clin Cancer Res. 2020 Feb 1;26(3):623-631. doi: 10.1158/1078-0432.CCR-19-0712. Epub 2019 Oct 22.

3.

Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma.

Wouters J, Vizoso M, Martinez-Cardus A, Carmona FJ, Govaere O, Laguna T, Joseph J, Dynoodt P, Aura C, Foth M, Cloots R, van den Hurk K, Balint B, Murphy IG, McDermott EW, Sheahan K, Jirström K, Nodin B, Mallya-Udupi G, van den Oord JJ, Gallagher WM, Esteller M.

BMC Med. 2017 Jun 5;15(1):101. doi: 10.1186/s12916-017-0851-3.

4.

Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.

Zuurbier L, Rahman A, Cordes M, Scheick J, Wong TJ, Rustenburg F, Joseph JC, Dynoodt P, Casey R, Drillenburg P, Gerhards M, Barat A, Klinger R, Fender B, O'Connor DP, Betge J, Ebert MP, Gaiser T, Prehn JHM, Griffioen AW, van Grieken NCT, Ylstra B, Byrne AT, van der Flier LG, Gallagher WM, Postel R.

Oncotarget. 2017 Jun 27;8(26):42949-42961. doi: 10.18632/oncotarget.17306.

5.

Prognostic and predictive biomarkers in melanoma: an update.

Foth M, Wouters J, de Chaumont C, Dynoodt P, Gallagher WM.

Expert Rev Mol Diagn. 2016;16(2):223-37. doi: 10.1586/14737159.2016.1126511. Epub 2015 Dec 22. Review.

PMID:
26620320
6.

miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells.

Dynoodt P, Speeckaert R, De Wever O, Chevolet I, Brochez L, Lambert J, Van Gele M.

Int J Oncol. 2013 Apr;42(4):1443-51. doi: 10.3892/ijo.2013.1823. Epub 2013 Feb 12.

PMID:
23404256
7.

Identification of miR-145 as a key regulator of the pigmentary process.

Dynoodt P, Mestdagh P, Van Peer G, Vandesompele J, Goossens K, Peelman LJ, Geusens B, Speeckaert RM, Lambert JL, Van Gele MJ.

J Invest Dermatol. 2013 Jan;133(1):201-9. doi: 10.1038/jid.2012.266. Epub 2012 Aug 16.

8.

Development of a 3D pigmented skin model to evaluate RNAi-induced depigmentation.

Van Gele M, Geusens B, Speeckaert R, Dynoodt P, Vanhoecke B, Van Den Bossche K, Lambert J.

Exp Dermatol. 2011 Sep;20(9):773-5. doi: 10.1111/j.1600-0625.2011.01319.x. Epub 2011 Jun 24.

PMID:
21707757
9.

Lipid-mediated gene delivery to the skin.

Geusens B, Strobbe T, Bracke S, Dynoodt P, Sanders N, Van Gele M, Lambert J.

Eur J Pharm Sci. 2011 Jul 17;43(4):199-211. doi: 10.1016/j.ejps.2011.04.003. Epub 2011 Apr 16. Review.

PMID:
21515366
10.

Griscelli syndrome: a model system to study vesicular trafficking.

Van Gele M, Dynoodt P, Lambert J.

Pigment Cell Melanoma Res. 2009 Jun;22(3):268-82. doi: 10.1111/j.1755-148X.2009.00558.x. Epub 2009 Feb 25. Review.

PMID:
19243575

Supplemental Content

Loading ...
Support Center